These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 23981744)

  • 21. Detection of HLA-B*58:01, the susceptible allele for allopurinol-induced hypersensitivity, by loop-mediated isothermal amplification.
    Kwok J; Kwong KM
    Br J Dermatol; 2013 Mar; 168(3):526-32. PubMed ID: 23066948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Personalized Medicine Approach to Guide Allopurinol Use and Prevent Serious Adverse Events: Ethnicity Is Not a Proxy for Genetics.
    Ikediobi O
    Clin Pharmacol Ther; 2021 Oct; 110(4):852-854. PubMed ID: 33330976
    [No Abstract]   [Full Text] [Related]  

  • 23. HLA-B58 can help the clinical decision on starting allopurinol in patients with chronic renal insufficiency.
    Jung JW; Song WJ; Kim YS; Joo KW; Lee KW; Kim SH; Park HW; Chang YS; Cho SH; Min KU; Kang HR
    Nephrol Dial Transplant; 2011 Nov; 26(11):3567-72. PubMed ID: 21393610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [HLA-B58.01 and allopurinol hypersensitivity renal vasculitis in a Chinese patient].
    Mariette F; Scarfoglière V; Giot M; Basire A; Rouby F; Daniel L; Jourde-Chiche N
    Rev Med Interne; 2022 Jul; 43(7):436-439. PubMed ID: 35606203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-induced severe cutaneous adverse reactions in Vietnamese.
    van Nguyen D; Chu HC; Vidal C; Fulton RB; Nguyen NN; Quynh Do NT; Tran TL; Nguyen TN; Thu Nguyen HT; Chu HH; Thanh Thuc HT; Minh Le HT; van Nunen S; Anderson J; Fernando SL
    Pharmacogenomics; 2021 Jan; 22(1):1-12. PubMed ID: 33356553
    [No Abstract]   [Full Text] [Related]  

  • 26. HLA alleles and drug hypersensitivity reactions.
    Profaizer T; Eckels D
    Int J Immunogenet; 2012 Apr; 39(2):99-105. PubMed ID: 22136512
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of a rapid and inexpensive assay for detecting a surrogate genetic polymorphism of HLA-B*58:01: a partially predictive but useful biomarker for allopurinol-related Stevens-Johnson syndrome/toxic epidermal necrolysis in Japanese.
    Maekawa K; Nishikawa J; Kaniwa N; Sugiyama E; Koizumi T; Kurose K; Tohkin M; Saito Y
    Drug Metab Pharmacokinet; 2012; 27(4):447-50. PubMed ID: 22277675
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis.
    Li X; Zhao Z; Sun SS
    Am J Health Syst Pharm; 2017 May; 74(9):e183-e192. PubMed ID: 28438823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison between the
    Saksit N; Nakkam N; Konyoung P; Khunarkornsiri U; Tassaneeyakul W; Chumworathayi P; Kanjanawart S; Sukasem C; Sangviroon A; Pattanacheewapull O; Tassaneeyakul W
    J Immunol Res; 2017; 2017():2738784. PubMed ID: 29392141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stevens-Johnson Syndrome in an Adult Filipino Male Positive for HLA-B*38:16 and B*58:17, Associated With Allopurinol: A Case Report.
    Reyes-Ramos AR; Preclaro IAC; Castillo MMS; Basco SES
    J Clin Pharmacol; 2023 Jun; 63(6):742-744. PubMed ID: 36790080
    [No Abstract]   [Full Text] [Related]  

  • 31. HLA-B*5801: a genetic susceptibility to allopurinol-induced DRESS.
    Mugwagwa AN; Fischer R; Zailan I
    Med J Aust; 2016 Mar; 204(4):159-60. PubMed ID: 26937673
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacogenetics of allopurinol--making an old drug safer.
    Lam MP; Yeung CK; Cheung BM
    J Clin Pharmacol; 2013 Jul; 53(7):675-9. PubMed ID: 23381951
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China.
    Cheng H; Yan D; Zuo X; Liu J; Liu W; Zhang Y
    Pharmacogenet Genomics; 2018 May; 28(5):117-124. PubMed ID: 29642234
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Lee HY; Pang SM; Thamotharampillai T
    J Am Acad Dermatol; 2008 Aug; 59(2):352-3. PubMed ID: 18638633
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacogenetics of toxic epidermal necrolysis.
    Lee MT; Hung SI; Wei CY; Chen YT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2153-62. PubMed ID: 20536296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.
    Cheng CY; Su SC; Chen CH; Chen WL; Deng ST; Chung WH
    J Immunol Res; 2014; 2014():565320. PubMed ID: 24901010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?
    Teng GG; Tan-Koi WC; Dong D; Sung C
    Pharmacogenomics; 2020 Mar; 21(4):279-291. PubMed ID: 32180492
    [No Abstract]   [Full Text] [Related]  

  • 38. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI
    Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetics and the potential for predictive tests in adverse drug reactions.
    Pirmohamed M
    Chem Immunol Allergy; 2012; 97():18-31. PubMed ID: 22613851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of Ocular Manifestation and Genetic Association of Allopurinol-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in South Korea.
    Lee HS; Ueta M; Kim MK; Seo KY; Sotozono C; Kinoshita S; Yoon KC
    Cornea; 2016 Feb; 35(2):199-204. PubMed ID: 26655481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.